These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30584162)

  • 1. Therapies to Slow, Stop, or Reverse Parkinson's Disease.
    Foltynie T; Langston JW
    J Parkinsons Dis; 2018; 8(s1):S115-S121. PubMed ID: 30584162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Parkinson's disease.
    Schapira AH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S41-3. PubMed ID: 20123556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents promote neuroprotection in Parkinson's disease models.
    Santos CM
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):410-8. PubMed ID: 22483311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE
    Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise and neuroplasticity in persons living with Parkinson's disease.
    Hirsch MA; Farley BG
    Eur J Phys Rehabil Med; 2009 Jun; 45(2):215-29. PubMed ID: 19532109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old and new challenges in Parkinson's disease therapeutics.
    Pires AO; Teixeira FG; Mendes-Pinheiro B; Serra SC; Sousa N; Salgado AJ
    Prog Neurobiol; 2017 Sep; 156():69-89. PubMed ID: 28457671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical approaches to the development of a neuroprotective therapy for PD.
    Olanow CW; Kieburtz K; Katz R
    Exp Neurol; 2017 Dec; 298(Pt B):246-251. PubMed ID: 28622912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstacles to the development of a neuroprotective therapy for Parkinson's disease.
    Stocchi F; Olanow CW
    Mov Disord; 2013 Jan; 28(1):3-7. PubMed ID: 23390094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.
    McFarthing K; Buff S; Rafaloff G; Fiske B; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2023; 13(4):427-439. PubMed ID: 37302040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of possible therapies for Parkinson's disease.
    Chakraborty A; Brauer S; Diwan A
    J Clin Neurosci; 2020 Jun; 76():1-4. PubMed ID: 32278516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
    Glavaski-Joksimovic A; Bohn MC
    Exp Neurol; 2013 Sep; 247():25-38. PubMed ID: 23542820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in Parkinson's disease-where do we stand?
    Toulouse A; Sullivan AM
    Prog Neurobiol; 2008 Aug; 85(4):376-92. PubMed ID: 18582530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.